Abstract
Testicular cancer is the most common solid tumor among men aged 15–35 years. The introduction of cisplatin-based chemotherapy has resulted in a cure rate of over 95% for men with testicular cancer, which has put increased emphasis on understanding the morbidity associated with chemotherapy. Hematological, gastrointestinal, gonadal, otological, renal, neurological, and pulmonary toxicities are the most common acute adverse effects. Although most patients recover, some of these effects can persist after the chemotherapy regimen has been completed and can become chronic problems. The late complications associated with cisplatin-based chemotherapy include secondary malignancies, cardiovascular disease, avascular necrosis, and cognitive impairment. Late complications can have considerable effects on survival and quality of life, so close monitoring of patients is critical for the early diagnosis of late adverse effects and to limit associated damage. All patients should adopt a healthy lifestyle and follow age-appropriate cancer screening programs. Hormonal supplementation should be considered for those with a low testosterone level, in order to reduce the risk of sexual dysfunction and metabolic syndrome. Prompt diagnosis of avascular necrosis is essential, and it should be considered in the differential diagnosis for any long-term testicular cancer survivor complaining of hip pain. Finally, sperm cryopreservation should be discussed with all patients before chemotherapy is initiated.
Key Points
-
Treatment-related complications in testicular cancer patients are dependent on the cumulative dose of chemotherapy agents, particularly cisplatin; prevention of these effects is important as testicular cancer is highly curable and usually affects young men
-
Myelosuppression, nausea, vomiting, transient elevation in liver enzymes, and ifosfamide-induced encephalopathy are the most common acute chemotherapy-related adverse effects, which are not usually associated with long-term sequelae
-
Infertility, gonadal dysfunction, nephrotoxicity, ototoxicity, peripheral neuropathy, Raynaud phenomenon, and pulmonary disorders are acute effects that may persist after chemotherapy is discontinued
-
Late sequelae of chemotherapy, which can develop many years after treatment, include secondary malignancies, cardiovascular disease, avascular necrosis, and cognitive dysfunction
-
Despite these toxicities, both the substitution of cisplatin with carboplatin or the reduction or delay of the cisplatin dose are contraindicated in testicular cancer patients treated with curative intent
-
Close monitoring of patients after chemotherapy is critical for diagnosis, prevention, and treatment of late sequelae; patients should adopt a healthy lifestyle, follow cancer screening programs, and consider sperm cryopreservation before chemotherapy begins
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
Walsh, T. J., Grady, R. W., Porter, M. P., Lin, D. W. & Weiss, N. S. Incidence of testicular germ cell cancers in US children: SEER program experience 1973 to 2000. Urology 68, 402–405 (2006).
Travis, L. B. et al. Testicular cancer survivorship: research strategies and recommendations. J. Natl Cancer Inst. 102, 1114–1130 (2010).
[No authors listed]. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol. 15, 594–603 (1997).
Mannuel, H. D. & Hussain, A. Update on testicular germ cell tumors. Curr. Opin. Oncol. 21, 254–259 (2009).
Nichols, C. R. et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J. Clin. Oncol. 16, 1287–1293 (1998).
Bajorin, D. F. et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J. Clin. Oncol. 11, 598–606 (1993).
Kondagunta, G. V. et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J. Clin. Oncol. 23, 9290–9294 (2005).
Kondagunta, G. V. et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549–6555 (2005).
Williams, S. D. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316, 1435–1440 (1987).
Loehrer, P. J. Sr, Gonin, R., Nichols, C. R., Weathers, T. & Einhorn, L. H. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J. Clin. Oncol. 16, 2500–2504 (1998).
de Wit, R. et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3 or 5 day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J. Clin. Oncol. 19, 1629–1640 (2001).
Bokemeyer, C. et al. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Ann. Hematol. 72, 1–9 (1996).
Feldman, D. R., Bosl, G. J., Sheinfeld, J. & Motzer, R. J. Medical treatment of advanced testicular cancer. JAMA 299, 672–684 (2008).
Khuri, F. R. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N. Engl. J. Med. 356, 2445–2448 (2007).
Fossa, S. D. et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J. Clin. Oncol. 21, 1107–1118 (2003).
Hesketh, P. J. et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21, 4112–4119 (2003).
Ajithkumar, T., Parkinson, C., Shamshad, F. & Murray, P. Ifosfamide encephalopathy. Clin. Oncol. (R. Coll. Radiol.) 19, 108–114 (2007).
Anderson, N. R. & Tandon, D. S. Ifosfamide extrapyramidal neurotoxicity. Cancer 68, 72–75 (1991).
Ghosn, M. et al. Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. Bull. Cancer 75, 391–392 (1988).
Samson, M. K. et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 53, 1029–1035 (1984).
Ginsberg, S. J. & Comis, R. L. The pulmonary toxicity of antineoplastic agents. Semin. Oncol. 9, 34–51 (1982).
White, D. A. & Stover, D. E. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest 86, 723–728 (1984).
Yousem, S. A., Lifson, J. D. & Colby, T. V. Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin. Chest 88, 103–106 (1985).
Comis, R. L. Detecting bleomycin pulmonary toxicity: a continued conundrum. J. Clin. Oncol. 8, 765–767 (1990).
Sleijfer, S. Bleomycin-induced pneumonitis. Chest 120, 617–624 (2001).
Bauer, K. A. et al. Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am. J. Med. 74, 557–563 (1983).
Blom-Muilwijk, M. C. et al. Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia. Studies in the rat. Br. J. Anaesth. 60, 91–97 (1988).
Hirsch, A. et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J. Clin. Oncol. 14, 1297–1305 (1996).
Sleijfer, S., van der Mark, T. W., Schraffordt Koops, H. & Mulder, N. H. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur. J. Cancer 32, 550–552 (1996).
Yagoda, A. et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann. Intern. Med. 77, 861–870 (1972).
Lower, E. E., Strohofer, S. & Baughman, R. P. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am. J. Med. Sci. 295, 193–197 (1988).
Collis, C. H. Lung damage from cytotoxic drugs. Cancer Chemother. Pharmacol. 4, 17–27 (1980).
Haugnes, H. S. et al. Pulmonary function in long-term survivors of testicular cancer. J. Clin. Oncol. 27, 2779–2786 (2009).
Sleijfer, S., van der Mark, T. W., Schraffordt Koops, H. & Mulder, N. H. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br. J. Cancer 71, 120–123 (1995).
Maher, J. & Daly, P. A. Severe bleomycin lung toxicity: reversal with high dose corticosteroids. Thorax 48, 92–94 (1993).
Vogelzang, N. J., Bosl, G. J., Johnson, K. & Kennedy, B. J. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann. Intern. Med. 95, 288–292 (1981).
Vogelzang, N. J., Torkelson, J. L. & Kennedy, B. J. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56, 2765–2770 (1985).
Stoter, G. et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J. Clin. Oncol. 7, 1099–1104 (1989).
Boyer, M. et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J. Clin. Oncol. 8, 21–26 (1990).
Glendenning, J. L. et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116, 2322–2331 (2010).
Meinardi, M. T. et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18, 1725–1732 (2000).
Brydøy, M. et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J. Natl Cancer Inst. 101, 1682–1695 (2009).
Adoue, D. & Arlet, P. Bleomycin and Raynaud's phenomenon. Ann. Intern. Med. 100, 770 (1984).
Bokemeyer, C., Berger, C. C., Kuczyk, M. A. & Schmoll, H. J. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J. Clin. Oncol. 14, 2923–2932 (1996).
Block, J. A. & Sequeira, W. Raynaud's phenomenon. Lancet 357, 2042–2048 (2001).
Fossa, S. D., Aass, N., Winderen, M., Bormer, O. P. & Olsen, D. R. Long-term renal function after treatment for malignant germ-cell tumours. Ann. Oncol. 13, 222–228 (2002).
Osanto, S. et al. Long-term effects of chemotherapy in patients with testicular cancer. J. Clin. Oncol. 10, 574–579 (1992).
Bissett, D. et al. Long-term sequelae of treatment for testicular germ cell tumours. Br. J. Cancer 62, 655–659 (1990).
Hartmann, J. T., Kollmannsberger, C., Kanz, L. & Bokemeyer, C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer 83, 866–869 (1999).
Fjeldborg, P., Sorensen, J. & Helkjaer, P. E. The long-term effect of cisplatin on renal function. Cancer 58, 2214–2217 (1986).
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
Gonzales-Vitale, J. C., Hayes, D. M., Cvitkovic, E. & Sternberg, S. S. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39, 1362–1371 (1977).
Moul, J. W., Robertson, J. E., George, S. L., Paulson, D. F. & Walther, P. J. Complications of therapy for testicular cancer. J. Urol. 142, 1491–1496 (1989).
Daugaard, G., Rossing, N. & Rorth, M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother. Pharmacol. 21, 163–167 (1988).
Reece, P. A., Stafford, I., Russell, J., Khan, M. & Gill, P. G. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J. Clin. Oncol. 5, 304–309 (1987).
Bosl, G. J. et al. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J. Clin. Oncol. 4, 1684–1689 (1986).
Loebstein, R. et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J. Clin. Pharmacol. 39, 454–461 (1999).
Skinner, R. Strategies to prevent nephrotoxicity of anticancer drugs. Curr. Opin. Oncol. 7, 310–315 (1995).
Aleksa, K., Woodland, C. & Koren, G. Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. Pediatr. Nephrol. 16, 1153–1158 (2001).
Cvitkovic, E., Spaulding, J., Bethune, V., Martin, J. & Whitmore, W. F. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39, 1357–1361 (1977).
Pera, M. F. Jr, Zook, B. C. & Harder, H. C. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Res. 39, 1269–1278 (1979).
Al-Sarraf, M. et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat. Rep. 66, 31–35 (1982).
Santoso, J. T., Lucci, J. A. 3rd, Coleman, R. L., Schafer, I. & Hannigan, E. V. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother. Pharmacol. 52, 13–18 (2003).
Horwich, A. et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J. Clin. Oncol. 15, 1844–1852 (1997).
Park, S. B. et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr. Med. Chem. 15, 3081–3094 (2008).
Ta, L. E., Espeset, L., Podratz, J. & Windebank, A. J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27, 992–1002 (2006).
Oldenburg, J. et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J. Transl. Med. 5, 70 (2007).
Gamelin, L. et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 10, 4055–4061 (2004).
van der Hulst, R. J., Dreschler, W. A. & Urbanus, N. A. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann. Otol. Rhinol. Laryngol. 97, 133–137 (1988).
Bokemeyer, C. et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer 77, 1355–1362 (1998).
Rybak, L. P. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr. Opin. Otolaryngol. Head Neck Surg. 15, 364–369 (2007).
Ross, C. J. et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345–1349 (2009).
Riedemann, L. et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 8, 23–28 (2008).
Oldenburg, J., Kraggerud, S. M., Cvancarova, M., Lothe, R. A. & Fossa, S. D. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25, 708–714 (2007).
Peters, U. et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11, 639–643 (2000).
Raman, J. D., Nobert, C. F. & Goldstein, M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J. Urol. 174, 1819–1822 (2005).
Richiardi, L. et al. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. J. Natl Cancer Inst. 96, 145–147 (2004).
Jacobsen, R. et al. Fertility and offspring sex ratio of men who develop testicular cancer: a record linkage study. Hum. Reprod. 15, 1958–1961 (2000).
Petersen, P. M., Skakkebaek, N. E., Vistisen, K., Rorth, M. & Giwercman, A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J. Clin. Oncol. 17, 941–947 (1999).
Lampe, H., Horwich, A., Norman, A., Nicholls, J. & Dearnaley, D. P. Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol. 15, 239–245 (1997).
DeSantis, M., Albrecht, W., Holtl, W. & Pont, J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int. J. Cancer 83, 864–865 (1999).
Pectasides, D. et al. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy. Eur. Urol. 45, 187–193 (2004).
Boekelheide, K. Mechanisms of toxic damage to spermatogenesis. J. Natl Cancer Inst. Monogr. 34, 6–8 (2005).
Leitner, S. P., Bosl, G. J. & Bajorunas, D. Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J. Clin. Oncol. 4, 1500–1505 (1986).
Brydøy, M. et al. Paternity following treatment for testicular cancer. J. Natl Cancer Inst. 97, 1580–1588 (2005).
Huddart, R. A. et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br. J. Cancer 93, 200–207 (2005).
Huyghe, E. et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 100, 732–737 (2004).
Herr, H. W., Bar-Chama, N., O'Sullivan, M. & Sogani, P. C. Paternity in men with stage I testis tumors on surveillance. J. Clin. Oncol. 16, 733–734 (1998).
Nuver, J. et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J. Clin. Oncol. 23, 3718–3725 (2005).
Lee, S. J. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 24, 2917–2931 (2006).
Bokemeyer, C. & Schmoll, H. J. Secondary neoplasms following treatment of malignant germ cell tumors. J. Clin. Oncol. 11, 1703–1709 (1993).
van Leeuwen, F. E. et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J. Clin. Oncol. 11, 415–424 (1993).
Travis, L. B. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst. 89, 1429–1439 (1997).
Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354–1365 (2005).
van den Belt-Dusebout, A. W. et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370–4378 (2007).
Richiardi, L. et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int. J. Cancer 120, 623–631 (2007).
Kaldor, J. M. et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int. J. Cancer 39, 571–585 (1987).
Hemminki, K., Liu, H. & Sundquist, J. Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann. Oncol. 21, 1546–1551 (2010).
Chaudhary, U. B. & Haldas, J. R. Long-term complications of chemotherapy for germ cell tumours. Drugs 63, 1565–1577 (2003).
Ratain, M. J. & Rowley, J. D. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann. Oncol. 3, 107–111 (1992).
Pedersen-Bjergaard, J. et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338, 359–363 (1991).
Boshoff, C. et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann. Oncol. 6, 35–40 (1995).
Bajorin, D. F., Motzer, R. J., Rodriguez, E., Murphy, B. & Bosl, G. J. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J. Natl Cancer Inst. 85, 60–62 (1993).
Nichols, C. R., Breeden, E. S., Loehrer, P. J., Williams, S. D. & Einhorn, L. H. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J. Natl Cancer Inst. 85, 36–40 (1993).
Travis, L. B. et al. Treatment-associated leukemia following testicular cancer. J. Natl Cancer Inst. 92, 1165–1171 (2000).
Feldman, D. R. The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization. Oncology (Williston Park) 24, 761–763 (2010).
van den Belt-Dusebout, A. W. et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 24, 467–475 (2006).
Huddart, R. A. et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513–1523 (2003).
Gietema, J. A. et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann. Intern. Med. 116, 709–715 (1992).
Fossa, S. D., Aass, N., Harvei, S. & Tretli, S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br. J. Cancer 90, 607–612 (2004).
Zagars, G. K., Ballo, M. T., Lee, A. K. & Strom, S. S. Mortality after cure of testicular seminoma. J. Clin. Oncol. 22, 640–647 (2004).
Lejonc, J. L., Vernant, J. P., Macquin, J. & Castaigne, A. Myocardial infarction following vinblastine treatment. Lancet 2, 692 (1980).
Airey, C. L., Dodwell, D. J., Joffe, J. K. & Jones, W. G. Etoposide-related myocardial infarction. Clin. Oncol. (R. Coll. Radiol.) 7, 135 (1995).
Licciardello, J. T., Moake, J. L., Rudy, C. K., Karp, D. D. & Hong, W. K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42, 296–300 (1985).
Nuver, J. et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J. Clin. Oncol. 23, 9130–9137 (2005).
Vaughn, D. J., Palmer, S. C., Carver, J. R., Jacobs, L. A. & Mohler, E. R. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 112, 1949–1953 (2008).
Bots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A. & Grobbee, D. E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432–1437 (1997).
Chambless, L. E. et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am. J. Epidemiol. 146, 483–494 (1997).
Wethal, T. et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J. Cancer Surviv. 1, 8–16 (2007).
Sagstuen, H. et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J. Clin. Oncol. 23, 4980–4990 (2005).
Haugnes, H. S. et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann. Oncol. 18, 241–248 (2007).
Shabsigh, R., Katz, M., Yan, G. & Makhsida, N. Cardiovascular issues in hypogonadism and testosterone therapy. Am. J. Cardiol. 96, 67M–72M (2005).
Makhsida, N., Shah, J., Yan, G., Fisch, H. & Shabsigh, R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J. Urol. 174, 827–834 (2005).
Laaksonen, D. E. et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur. J. Endocrinol. 149, 601–608 (2003).
Gietema, J. A., Meinardi, M. T., van der Graaf, W. T. & Sleijfer, D. T. Syndrome X in testicular-cancer survivors. Lancet 357, 228–229 (2001).
Winquist, E. W., Bauman, G. S. & Balogh, J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am. J. Clin. Oncol. 24, 603–606 (2001).
Cook, A. M., Dzik-Jurasz, A. S., Padhani, A. R., Norman, A. & Huddart, R. A. The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Br. J. Cancer 85, 1624–1626 (2001).
Kaila, R. & Wolman, R. L. Groin pain in athletes: a consequence of femoral head avascular necrosis after testicular cancer chemotherapy. Clin. J. Sport. Med. 16, 175–176 (2006).
van den Berkmortel, F., de Wit, R., de Rooy, J. & DeMulder, P. Osteonecrosis in patients with testicular tumours treated with chemotherapy. Neth. J. Med. 62, 23–27 (2004).
Harper, P. G., Trask, C. & Souhami, R. L. Avascular necrosis of bone caused by combination chemotherapy without corticosteroids. Br. Med. J. (Clin. Res. Ed.) 288, 267–268 (1984).
Schagen, S. B. et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 47, 63–70 (2008).
Pedersen, A. D. et al. Long-term cognitive function following chemotherapy in patients with testicular cancer. J. Int. Neuropsychol. Soc. 15, 296–301 (2009).
Skaali, T. et al. A prospective study of neuropsychological functioning in testicular cancer patients. Ann. Oncol. doi:10.1093/annonc/mdq553.
Dahl, A. A. et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J. Clin. Oncol. 23, 2389–2395 (2005).
Author information
Authors and Affiliations
Contributions
C. Fung researched data for, and wrote, the article. D. J. Vaughn and C. Fung made substantial contributions to dicussion of content and reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Fung, C., Vaughn, D. Complications associated with chemotherapy in testicular cancer management. Nat Rev Urol 8, 213–222 (2011). https://doi.org/10.1038/nrurol.2011.26
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.26
This article is cited by
-
Cisplatin treatment induces attention deficits and impairs synaptic integrity in the prefrontal cortex in mice
Scientific Reports (2018)
-
Carvedilol alleviates testicular and spermatological damage induced by cisplatin in rats via modulation of oxidative stress and inflammation
Archives of Pharmacal Research (2016)
-
Adverse effects of common medications on male fertility
Nature Reviews Urology (2015)
-
Effects of combined treatment of α-tocopherol, l-ascorbic acid, selenium and zinc on bleomycin, etoposide and cisplatin-induced alterations in testosterone synthesis pathway in rats
Cancer Chemotherapy and Pharmacology (2014)
-
Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells
Cell Death & Disease (2013)